Posts tagged disorders
ProMIS announces new AZ program

ProMIS Neurosciences (TSX:PMN) has initiated a program to identify novel therapeutic targets on neurotoxic strains of the protein tau, which, like neurotoxic strains of Amyloid beta (Ab), are implicated in the development of Alzheimer’s disease (AD).

“With multiple product candidates in our Ab program progressing to final validation and selection for drug development, we are focusing our science team and discovery processes on the other half of the root cause – tau prions.” SCO, Dr. Neil Cashman, explained in a statement.

Read More
Anavex posts positive preclinical results in Fragile X

Anavex Life Sciences (NASDAQ:AVXL) has reported positive data for ANAVEX 2-73 in an exploratory study in a Fragile X syndrome model presented at the Gordon Research Conference for Fragile X and Autism-Related Disorder in Mount Snow, VT.

Fragile X syndrome is the most common form of inherited intellectual disability and the most frequent single gene cause of autism.

Read More
HCW transfers coverage of uniQure at buy

Mark Breidenback of H.C. Wainwright has assumed coverage of uniQure NV (NASDAQ:QURE) with a “buy” rating and $30 price target. The stock closed at $14.89 on Tuesday.

uniQure is developing gene therapies as long-acting, potentially curative treatments for several monogenic, inherited disorders. The company’s core franchise is comprised of a broadly applicable technology platform that produced Europe’s first approved gene therapy, Glybera.

Read More